



Supplemental Figure 1 Quality control of single-cell data for PBMC samples from gout patients. (A) Dual energy CT picture of gout patient. (B) Summary of captured cells, median genes per cell, median UMIs per cell, and the number of cells that passed quality control (QC) in distinct batches of single-cell data from gout patients. (C) Box plots showing the gene number (top panel), UMI number (bottom left panel), and percentage of mitochondrial RNA (bottom right panel) in distinct batches of single-cell data from gout patients. (D) tSNE of the total cells profiled here, with each cell color-coded for: the clusters (left), the group (median), the corresponding patient(right).




Supplemental Figure 2 Detailed characterization of monocyte subtypes from the gout flare and remission of gout. (A) Bar plot of cell fractions of myeloid subtypes stratified by groups. (B) Violin plots of the average expression of genes involved in the inflammatory cytokines in each monocyte subtypes from gout flare and remission. P values were calculated using two-sided Wilcoxon rank-sum tests. Data are from single-cell transcriptomes of 3 independent gout patients. *** $P < 0.001$ (C) Heatmap of the t values of AUC scores of expression regulation by transcription factors in each monocyte subtypes from gout flare and remission, as estimated using SCENIC. (D) Gene expression changes of selected marker genes as a function of pseudotime reflecting the cellular differentiation. (E) DEG analysis as a function of pseudotime in a branch-dependent manner showing a common gene signature of a pre-branch precursor cell population choosing two main cell fates.




Supplemental Figure 3 Flow cytometry of monocyte subtypes from the gout flare and remission of gout. (A-B) Percentages of PBMCs, single cells, live cells, CD45⁺ cells, CD11b⁺ cells, classical monocytes, HLA-DQA1⁺ classical monocytes, non-classical monocytes and HLA-DQA1⁺ non-classical monocytes in gout flare (A) and gout remission patients (B). Cells were gated on lymphocytes and one representative flow cytometry chart from each group is shown. (C) Box plots of the percentages of monocyte subtypes. The box represents the interquartile range (IQR). The horizontal line inside the box represents the median. The whiskers extend from the box, indicating

the data range without outliers. Outliers are shown as individual points beyond the whiskers and defined as values outside 1.5 times the IQR range. Statistical analysis was undertaken using a 2-tailed Student's t test.




Supplemental Figure 4 The role of CD4+ T cell subtypes in gout flare and remission. (A) Bar plot of cell fractions of CD4+ TC subtypes stratified by groups. **(B)** The volcano plot represents the top differentially expressed genes of KLRB1+ CD4+ TC and Treg cells between gout flare and remission. **(C-D)** Box plots of the expression of genes involved in the top KEGG pathways term of KLRB1+ CD4+ TCs **(C)** and Treg cells **(D)** between gout flare and remission. *P* values were

determined by the Wilcoxon rank-sum tests. Data are from single-cell transcriptomes of 3 independent gout patients. *** $P < 0.001$ (E-F) Percentages of TCs, CD4⁺ TCs, Th1 cells, Th2 cells, Th17 cells, and Treg in gout flare patients (E) and gout remission patients (F). Cells were gated on lymphocytes and one representative flow cytometry chart from each group is shown.




Supplemental Figure 5 The role of CD8⁺ T cell subtypes in gout flare and remission. (A) Bar plot of cell fractions of CD8⁺ TC subtypes stratified by groups. **(B)** Heatmaps of DE genes between CD8⁺ TC subtypes of gout flare compared to remission of gout. The heatmap is colored by average $\log(\text{FC})$. All displayed genes and regulators are statistically significant at the $P < 0.05$. **(C)** The volcano plot represents the top differentially expressed genes of naïve CD8⁺ TCs and cytotoxic CD8⁺ TCs between gout flare and remission. **(D)** tSNE plots showing the expression of selected cytokines in CD8⁺ TC subtypes. **(E)** Naïve CD8⁺ TCs and cytotoxic CD8⁺ TCs functional enrichment analysis with KEGG of each monocyte subtypes were performed with up and down

regulated genes.




Supplemental Figure 6 The role of NK cells subtypes in gout flare and remission. (A) Bar plot of cell fractions of NK cell subtypes stratified by groups. (B) Heatmaps of DE genes between NK cell subtypes of gout flare compared to remission of gout. The heatmap is colored by average $\log_2(\text{FC})$. All displayed genes and regulators are statistically significant at the $P < 0.05$. (C) The volcano plot represents the top differentially expressed genes of NK cell subtypes between gout flare and remission. (D) tSNE plots showing the expression of selected cytokines in NK cell subtypes. (E) NK cells functional enrichment analysis with KEGG of each monocyte subtypes were

performed with up and down regulated genes.




Supplemental Figure 7 The role of Treg cell subtypes in gout flare and remission. (A) t-SNE representations of integrated single-cell transcriptomes of Treg cells, cells are color-coded by clusters and disease state. (B) Heatmap of all clusters from Treg cells after dimensional reduction. Top 100 marker genes were used and colored by their expression level. (C) Bar plot showing cell fractions of Treg subtypes in patients with gout flare and gout remission, color coded for cell clusters. (D) Violin plots of the average expression of genes involved in the function in Treg cells from gout flare and remission. (E) Treg cell suppression assay. Sorted Tregs ($CD4^+CD25^+CD127^-$) were co-cultured with eFluor 450-labeled Teffs ($CD4^+CD25^-$) at different Treg-to-Teff ratios in the presence of anti-CD3/CD28 beads. The percentages of divided T cells are shown in each histogram plot.




Supplemental Figure 8 Some cell–cell communications mediated by signaling pathways are greatly altered in gout flare compared with remission. (A) Significant signaling pathways were ranked based on differences in the overall information flow within the inferred networks between gout flare and remission. The overall information flow of a signaling network is calculated by summarizing all communication probabilities in that network. Red-colored labels are more enriched in the gout flare, black-colored labels are equally enriched in gout flare and remission, blue-colored labels are enriched in gout remission. Circle plots show and compare cell–cell communication alterations between gout flare and remission mediated by some of the signaling axes, including C-


C Motif Chemokine Ligand (CCL) (B), IL16 (C), Intercellular Adhesion Molecule (ICAM) (D), Integrin Subunit (ITGB2) (E), Class II Major Histocompatibility Complex (MHC-II) (F), NOTCH (G), Thrombospondin (THBS) (H) and Inducible T Cell Costimulator (ICOS) (I).



Supplemental Figure 9 Inflammatory score and cytokine score of cell subtypes between gout flare and remission. (A-B) t-SNE plots of PBMCs colored by cytokine score (A), and inflammatory score (B). (C-D) t-SNE plots of myeloid cells colored by cytokine score (C), and inflammatory score (D). (E) Boxplots of the cytokine score (top panel) and inflammatory score (bottom panel) of cell subtypes. Significance was evaluated with the t-test. Data are from single-cell transcriptomes of 3 independent gout patients. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.



Supplemental Figure 10 Detailed characterization of arachidonic acid metabolic activity for the gout flare and remission. (A) t-SNE plots of PBMCs (left panel) and myeloid cells (right panel) colored by arachidonic acid score in gout flare and remission. (B) Boxplots of the arachidonic acid score of cell subtypes. Significance was evaluated with the t-test. Data are from single-cell transcriptomes of 3 independent gout patients. * $P < 0.05$, ** $P < 0.001$, *** $P < 0.001$, **** $P < 0.0001$. (C) 2D PCA score plots and 2D scatter plot for the orthogonal projections to latent structures discriminant analysis (OPLS-DA) show visual separation of gout flare (red dots) from the remission (blue dots). (D) S-plot and VIP value of the analysis of OPLS-DA. (E) Plasma levels of ten significant expressed metabolites from gout flare ($n = 9$) and remission ($n = 9$) patients. The box represents the interquartile range (IQR). The horizontal line inside the box represents the median. The whiskers extend from the box, indicating the data range without outliers. Outliers are shown as individual points beyond the whiskers and defined as values outside 1.5 times the IQR range. Statistical analysis was undertaken using a 2-tailed Student's t test. * $P < 0.05$, ** $P < 0.001$, *** $P < 0.001$.



Supplemental Figure 11 Flow cytometry of CD4⁺ T cells subtypes in normal control, gout flare and remission. Boxplots of the percentages of T cells, CD4⁺ T cells, Th17 cells and Treg in normal control (n = 120), gout flare (n = 41) and remission (n = 35) patients. The box represents the interquartile range (IQR). The horizontal line inside the box represents the median. The whiskers extend from the box, indicating the data range without outliers. Outliers are shown as individual points beyond the whiskers and defined as values outside 1.5 times the IQR range. Statistical analysis was done using the Kruskal-Wallis test followed by Dunn's multiple comparison correction. * $P < 0.05$, ** $P < 0.001$, **** $P < 0.0001$

Supplemental Table 1 Percentages of monocyte subtypes between gout flare and remission by flow cytometry

Number	Sample ID	group	PBMC	SingleCells	Live	CD45+	CD11b+	Nonclassical	Nonclassical+,HLA-DQA1+	classical	Classical+,HLA-DQA1+
Specimen_001_A11_066.fcs	AG11	Acute flare	39.00%	95.50%	97.10%	98.20%	39.40%	26.30%	7.14%	38.90%	8.41%
Specimen_001_A14_017.fcs	AG14	Acute flare	31.50%	97.50%	98.50%	96.30%	15.60%	17.30%	5.98%	30.80%	19.10%
Specimen_001_A16_057.fcs	AG16	Acute flare	55.90%	97.10%	96.70%	98.30%	32.40%	6.18%	8.04%	7.87%	9.01%
Specimen_001_A21_070.fcs	AG21	Acute flare	57.40%	98.20%	86.80%	95.60%	27.10%	27.50%	3.10%	2.77%	5.34%
Specimen_001_A23_071.fcs	AG23	Acute flare	16.10%	96.00%	89.10%	96.10%	27.20%	42.40%	3.01%	19.00%	5.02%
Specimen_001_A24_072.fcs	AG24	Acute flare	20.70%	96.40%	89.70%	92.90%	28.40%	18.20%	6.12%	7.34%	10.50%
Specimen_001_A33_078.fcs	AG33	Acute flare	16.40%	96.20%	92.30%	94.00%	27.70%	38.20%	10.30%	11.40%	10.50%
Specimen_001_A36_080.fcs	AG36	Acute flare	18.20%	94.00%	87.40%	96.10%	51.10%	30.40%	15.00%	13.00%	10.20%
Specimen_001_A40_019.fcs	AG40	Acute flare	55.80%	97.90%	97.40%	99.10%	45.60%	27.30%	2.05%	22.40%	11.40%
Specimen_001_A41_083.fcs	AG41	Acute flare	34.70%	95.70%	68.80%	96.70%	44.10%	23.70%	9.84%	3.08%	16.10%
Specimen_001_A42_020.fcs	AG42	Acute flare	47.20%	98.30%	90.40%	98.40%	41.20%	19.20%	3.13%	9.66%	21.80%
Specimen_001_A43_021.fcs	AG43	Acute flare	12.40%	96.10%	89.20%	96.00%	40.00%	29.50%	3.25%	8.28%	13.10%
Specimen_001_A44_084.fcs	AG44	Acute flare	24.60%	94.40%	80.10%	95.90%	47.20%	22.60%	12.90%	5.81%	15.80%
Specimen_001_A49_087.fcs	AG49	Acute flare	10.50%	97.70%	93.60%	94.00%	25.40%	16.80%	6.69%	20.40%	17.40%
Specimen_001_A50_088.fcs	AG50	Acute flare	11.80%	96.80%	93.10%	94.50%	35.70%	31.20%	4.24%	17.80%	15.70%
Specimen_001_A53_090.fcs	AG53	Acute flare	9.60%	94.80%	94.50%	93.00%	45.80%	36.30%	3.29%	16.80%	17.40%
Specimen_001_A54_091.fcs	AG54	Acute flare	19.00%	96.90%	84.60%	94.80%	46.80%	28.80%	7.65%	10.70%	9.18%
Specimen_001_A55_092.fcs	AG55	Acute flare	13.70%	96.30%	80.70%	94.00%	39.60%	34.90%	5.40%	6.32%	14.40%
Specimen_001_A56_093.fcs	AG56	Acute flare	16.60%	96.80%	84.60%	96.30%	29.80%	39.50%	6.24%	17.40%	5.73%
Specimen_001_A58_095.fcs	AG58	Acute flare	46.60%	96.20%	80.90%	95.00%	25.80%	18.20%	9.93%	6.27%	14.80%
Specimen_001_A59_096.fcs	AG59	Acute flare	50.60%	95.70%	82.90%	95.30%	41.10%	11.10%	9.23%	17.70%	11.10%
Specimen_001_G1_027.fcs	RG1	Remission	15.50%	97.90%	94.70%	94.20%	13.00%	17.30%	3.85%	27.20%	24.70%
Specimen_001_G2_028.fcs	RG2	Remission	26.00%	97.10%	72.80%	94.90%	14.60%	14.40%	3.68%	14.70%	20.30%
Specimen_001_G3_029.fcs	RG3	Remission	15.70%	98.20%	97.30%	96.20%	25.20%	30.30%	5.83%	24.10%	8.45%
Specimen_001_G4_026.fcs	RG4	Remission	28.90%	96.20%	98.20%	96.30%	17.40%	22.80%	4.43%	24.30%	21.30%
Specimen_001_G5_031.fcs	RG5	Remission	22.30%	97.50%	89.20%	93.80%	20.70%	37.90%	10.20%	12.90%	28.60%
Specimen_001_G6_030.fcs	RG6	Remission	30.10%	97.30%	93.40%	98.70%	38.60%	38.60%	2.90%	10.80%	24.70%
Specimen_001_G7_032.fcs	RG7	Remission	31.70%	98.10%	85.80%	98.60%	24.90%	45.30%	5.01%	13.90%	8.33%
Specimen_001_G9_033.fcs	RG9	Remission	31.90%	97.10%	77.40%	97.50%	32.90%	32.80%	5.87%	8.91%	15.50%
Specimen_001_G10_045.fcs	RG10	Remission	23.70%	97.10%	89.90%	91.00%	41.10%	43.90%	2.31%	8.70%	7.50%
Specimen_001_G11_050.fcs	RG11	Remission	11.40%	96.30%	96.20%	96.20%	23.30%	9.69%	4.48%	18.20%	8.73%
Specimen_001_G12_034.fcs	RG12	Remission	23.30%	95.90%	80.80%	95.80%	25.10%	10.30%	8.04%	26.00%	13.50%
Specimen_001_G13_035.fcs	RG13	Remission	26.10%	96.20%	78.10%	96.20%	40.30%	37.70%	5.22%	3.82%	13.90%
Specimen_001_G14_058.fcs	RG14	Remission	8.08%	93.60%	81.80%	90.20%	36.70%	40.10%	6.45%	12.80%	18.90%
Specimen_001_G15_059.fcs	RG15	Remission	11.10%	93.80%	88.80%	97.90%	25.20%	31.70%	4.66%	11.40%	8.34%
Specimen_001_G19_051.fcs	RG19	Remission	8.50%	95.80%	96.10%	95.60%	40.10%	39.80%	3.89%	33.60%	11.50%
Specimen_001_G20_060.fcs	RG20	Remission	23.60%	97.40%	79.40%	92.70%	31.90%	18.80%	2.75%	28.00%	8.11%
Specimen_001_G21_061.fcs	RG21	Remission	40.30%	93.00%	80.30%	94.40%	36.00%	10.10%	7.75%	9.33%	7.91%
Specimen_001_G22_062.fcs	RG22	Remission	21.30%	95.70%	85.20%	92.40%	54.40%	25.60%	4.55%	13.10%	12.80%
Specimen_001_G23_063.fcs	RG23	Remission	16.00%	96.10%	98.90%	80.20%	23.20%	50.00%	5.64%	29.10%	9.78%
Specimen_001_R14_022.fcs	R14	Remission	23.70%	96.80%	96.20%	96.60%	18.10%	36.60%	3.81%	25.10%	12.50%
Specimen_001_R16_054.fcs	RG16	Remission	56.10%	96.70%	98.50%	97.90%	29.40%	27.70%	6.39%	13.10%	6.74%
Specimen_001_R42_024.fcs	RG42	Remission	33.90%	98.30%	86.60%	98.00%	47.40%	39.10%	3.06%	6.15%	11.70%
Specimen_001_R43_025.fcs	RG43	Remission	32.50%	98.20%	98.00%	94.40%	31.00%	16.20%	0.17%	43.60%	2.51%

Supplemental Table 2 Percentages of Treg cells between gout flare and remission by flow cytometry

Sample ID	Group	T cells (% of lymphocyte)	CD4 ⁺ T cells (% of T cells)	Th1 (% of Th cells)	Th2 (% of Th cells)	Th17 (% of Th cells)	Treg cells (% of T cells)
AG1	Acute flare	54.6	51.7	8.64	27.7	1.01	3.23
A2	Acute flare	65.9	51	28	9.08	1.26	3.39
AG4	Acute flare	73.3	79.9	38.3	13.4	1.3	2.2
AG7	Acute flare	76.6	30.5	16.5	11.7	1.51	1.1
A8	Acute flare	65.3	54.6	26.2	10.9	2.24	2.11
A9	Acute flare	54.5	65.9	13.6	21.2	2.53	2.84
A10	Acute flare	72.2	38.7	30.9	13.6	0.86	1.62
A13	Acute flare	61.7	65.8	27.5	9.35	2.6	2.62
AG12	Acute flare	75.5	43.6	41.3	8.74	0.6	2.52
AG11	Acute flare	58.3	62.7	31.6	21.4	2.28	3.71
AG14	Acute flare	61.8	62.4	26.3	20	2.42	5.66
AG16	Acute flare	83.4	55.7	30.5	5.7	0.62	2.82
AG21	Acute flare	71.6	64.6	20.7	16.6	0.9	4.79
AG23	Acute flare	74.8	47.4	24.5	13.2	1.17	3.98
AG24	Acute flare	45.2	58.5	13.8	6.47	0.54	9.32
AG33	Acute flare	59.4	57.5	15.1	11.9	0.76	5.74
AG36	Acute flare	48.8	54.7	23.7	15.4	1.75	4.77
AG40	Acute flare	65.8	52.8	11.4	19.9	0.62	3.7
AG41	Acute flare	72.2	59.4	55.5	9.28	1.14	3.76
AG42	Acute flare	64.2	58.4	7.65	24.2	1.28	5.63
AG43	Acute flare	74.7	48.3	17.6	18.5	1.39	2.9
AG44	Acute flare	75.5	51.6	20.2	16.4	1.23	3.04
AG49	Acute flare	74.9	59.6	19.1	25.7	1	3.73
AG50	Acute flare	68	52.1	8.89	42.4	0.52	4.28
A52	Acute flare	78.7	79.4	15.9	17.7	1.39	7.55
AG53	Acute flare	47.7	55.9	21.4	23.4	7.18	3
AG59	Acute flare	57.8	57.5	9.57	18.5	12.8	4.1
A1	Acute flare	75.7	58.4	9.24	28.6	18.6	2.48
AG3	Acute flare	69.4	64.2	29.5	11	4.51	3.68
A3	Acute flare	64.3	57.4	17.5	15	4.67	4.05
AG5	Acute flare	58.1	64.4	17.6	10.6	1.9	4.16
AG6	Acute flare	86.9	71	18.2	12.5	3.04	3.02
AG8	Acute flare	61.5	86.3	12.6	26	1.91	3.63
AG9	Acute flare	72.8	66.6	10.1	16.1	8.95	4.54
AG10	Acute flare	38.2	34.3	6.56	17.2	2.81	1.57
AG13	Acute flare	72.5	60	29	8.32	1.74	3.98
AG15	Acute flare	72.5	61.8	12.6	21.5	2.59	3.62
AG19	Acute flare	70.5	47.7	3.87	19.8	4.76	3.86
AG17	Acute flare	82.7	64.4	8.79	13	0.55	3.66
AG20	Acute flare	50.4	76.7	16.7	15.5	2.93	3.1
AG18	Acute flare	69.5	53	21.3	16.8	1.2	2.08
P2	Remission	79.7	57.5	22.3	9.08	1.53	3.12
G7	Remission	71.9	65.5	14.5	22	1.54	2.91
G8	Remission	68.7	51.9	22.7	11.3	1.15	2.62
G9	Remission	60.7	67.8	13.6	20.8	2.16	3.57
G10	Remission	66.4	72.6	22.3	8.6	2.78	4.8
G13	Remission	77.2	38.7	20.8	19.9	2.26	1.93
RG42	Remission	70.9	57.5	11.3	10.4	1.24	5.08
RG43	Remission	77.7	51.2	10	26.2	1.43	3.81
G52	Remission	75.7	80.1	10.7	12.3	1.53	7.37
G22	Remission	67.1	53.9	27.4	9.44	1.17	3.78
G23	Remission	44.1	57.2	8.69	13.9	3.11	6.41
R28	Remission	90.7	80.2	18	8.16	1.21	5.07
R29	Remission	59.4	66	39.7	17.7	4.57	2.88
R30	Remission	45.6	53.2	4.24	8.77	1.57	2.79
R31	Remission	22.7	85.3	14.4	18.7	1.66	9.72
RG9	Remission	58.8	68.9	17.4	25.3	2.22	5
RG11	Remission	83.8	38.3	27.6	18.8	1.23	2.5
RG14	Remission	63.8	68.8	10.8	17.5	1.31	6.84
RG39	Remission	55.8	79.2	26.2	17.6	0.99	6.17
RG1	Remission	78.1	66.3	35.2	19	1.75	10.1
RG2	Remission	73.6	70.9	30.3	19.6	1.32	11.9
RG6	Remission	67.9	57.1	15.2	24.4	1.03	5.41
RG13	Remission	66.8	40.6	14.8	29.6	0.81	2.67
RG56	Remission	60.8	75.8	16.2	18.2	1.79	6
RG32	Remission	54.4	71.4	11.2	13	6.95	4.21
RG33	Remission	86.1	53.6	22.4	14.2	3.83	5.67
RG34	Remission	73	65.8	19.8	22.3	2.38	4.94
RG35	Remission	78.9	70.9	16.9	12.1	2.37	3.65
RG36	Remission	77.6	65.6	8.33	13.6	1.76	5.65
RG37	Remission	63.9	49.4	9.18	22.3	5.42	3.44
RG38	Remission	82.3	76.4	6.64	12.6	0.25	2.69
RG49	Remission	65.5	59	16	15.9	5.53	4.42
RG40	Remission	44.8	53.8	11.3	23.8	5.21	4.7
RG41	Remission	82.1	92.4	4.98	11.9	2.05	4.4
RG44	Remission	64.5	63.7	18.2	9.04	0.98	5.77

Supplemental Table 3 A gene list associated with cytokine, inflammatory response and arachidonic acid pathway

Cytokines	Inflammatory	Arachidonic acid pathway
IL2	ABCA1	AKR1C3
IL7	AB1	ALOX12
CSF3	ACVRI1B	ALOX12B
CCCL10	ACVRI2A	ALOX15
CCL2	ADGRE1	ALOX15B
CCL3	ADM	ALOX5
TNF	ADORA2B	CBR1
TFTN1	ADRM1	CBR3
IL6	AHR	CYP2B6
CCL7	APLR	CYP2C18
IL1RN	AP3	CYP2C19
CSF1	AT2A2	CYP2C9
IFNG	AT2B1	CYP2C9
IL2RA	AT2C1	CYP2E1
IL10	AXL	CYP2J2
IL18	BDKRB1	CYP2U1
HGF	BEST1	CYP4A11
CXCL9	BST2	CYP4A22
CCL27	BTG2	CYP4F2
TGFB1	C3AR1	CYP4F3
IL1B	CSAR1	EPHX2
LTA	CALCR	GGT1
CSF2	CCL17	GGT6
LTB	CCL2	GGT6
TNFSF13	CCL20	GGT7
IL4	CCL22	GPX1
CCL12	CCL24	GPX2
CXCL8	CCL5	GPX3
CXCL11	CCL7	GPX4
CCL4	CCR7	GPX5
CXCL2	CCR2	GPX6
CXCL3	CD14	GPX7
CCL3L1	CD40	HPGD5
CCL8	CD48	JMJD1-PLA2G4B
CXCL16	CD55	LTA4H
IFNA1	CD68	LTC4S
CCL5	CD70	PLA2G10
CCL11	CD82	PLA2G12A
IFNA2	CDKN1A	PLA2G12B
CCL20	CHST2	PLA2G1B
CCL4E2	CLEC10A	PLA2G2A
OSM	CMKLR1	PLA2G2C
TNFSF14	CSF1	PLA2G2D
SA100A12	CSF3	PLA2G2E
FGF19	CSF3R	PLA2G2F
CXCL5	CXCL10	PLA2G3
CCL19	CXCL11	PLA2G4A
IL18R1	CXCL6	PLA2G4B
TGFA	CXCL8	PLA2G4E
IFNH1	CXCL9	PLA2G5
IL8	CXCR6	PTGS5
IL17C	CTBB	PTGS6
TNFSF10	DCBLD2	PTGS62
FGF7	EB3	PTGS
XCL1	EDN1	PTGS1
FGF13	EF2AK2	PTGS2
LIF	EM2	PTGS2
TGFB3	EREG	TBXA51
INHBE	FS	
CERS1	FFAR2	
TXLNA	FRP1	
IFNW1	FDX	
IL22	GABBR1	
XCL2	GCH1	
CCL20	GNAS1	
CCL16	GNAS3	
CDM1G	GPIBA	
IL20	GPC3	
FASLG	GPR132	
TPO	GPR183	
SCYL3	HAS2	
PCAF1	HREGF	
TNFSF8	HIF1A	
GFY15	HRH1	
IL1A	HRH1	
VEGFA	ICAM1	
GDF7	ICAM4	
BMPE	ICSLG	
PDGFA	IFTM1	
IL21	IFNAR1	
ABCD1	IFNGR2	
ABCD2	IL10	
PDGFB	IL10RA	
TNFSF4	IL12B	
FAM19A1	IL15	
HREGF	IL18RA	
PDGFD	IL15	
IL12RB2	IL18R1	
GM1	IL18RAP	
VEGFB	IL1A	
MIP2B	IL1B	
IL27	IL1R1	
PF4	IL2RB	
BMPEB	IL4R	
TNFSF12	IL6	
IL15	IL7R	
SCYL2	INHBA	
SCYL1	IRAK2	
TSFP	IRF1	
GDF11	IRF7	
SEPIB	ITGAE	
INHBA	ITGB3	
PPBP	ITGB8	
FGF11	KCNA3	
IFNG-AS1	KCNJ2	
FGF22	KCNMB2	
VEGFC	KIF1B	
CCL16	KLFB	
TNFSF11	LAMP3	
IL12A	LCK	
EB3	LC2P	
AMH	LDLR	
IL36	LIF	
IL32	LPAR1	
PDGFC	LTA	
FGF23	LYVE	
IGF1	LYN	
IL1F1	MARGO	
CCL28	MEFV	
CCL21	MEP1A	
TNFSF9	MET	
BMPE	MMP14	
IL24	MIR1	
GDF10	MXD1	
CXCL5	MTC	
GDF9	NAMPT	
IL23A	NIP	
IL16	NKKB1	
CD70	NKKB1A	
IL5	NLRP3	
FGF9	NMI	
IFNL1	NMUR1	
TSO1	NO2	
FGF2	NPFFR2	
IL23R	OLR1	
IL16	OPRK1	
SP1	OSM	
IL12RB1	OSMR	
BMPE	P2RX4	
IL13	P2RX7	
TPAR1	P2RY2	
TGFB2	PCHN7	
FAM19A2	PDE4B	
AGF3	PDPR	
EDA	PKRIS	
MF	PLAUR	
TNFSF13B	PROK2	
BMPE	PSEN1	
FGF18	PTAFR	
CCL23	PTGER2	
	PTGER4	
	PTGR	
	PTPRE	
	PVR	
	RAF1	
	RASGRP1	
	RELA	
	RO51	
	RO516	
	RHOQ	
	RPK2	
	RNF44B	
	RO51	
	RTK4	
	SCARF1	
	SCN1B	
	SELE	
	SELENOS	
	SELL	
	SEMA4D	
	SERPINE1	
	SERP2	
	SLAMF1	
	SLC11A2	
	SLC1A2	
	SLC39A2	
	SLC31A1	
	SLC31A2	
	SLC4A4	
	SLC7A1	
	SLC7A2	
	SPHK1	
	SRI	
	STAB1	
	TACR1	
	TACR3	
	TAPBP	
	TIMP1	
	TLR1	
	TLR2	
	TLR3	
	TNFAIP6	
	TNFRSF18	
	TNFRSF9	
	TNFRSF10	
	TNFRSF16	
	TNFRSF17	
	TNFRSF9	
	TPSD	
	VIP	

Supplemental Table 5 Baseline characteristics and laboratory findings of gout flare and gout remission in scRNA-seq study

Patient number	P1		P2		P3	
Age, years	53		53		23	
Gender	male		male		male	
Height, cm	177		178		175	
Weight, kg	69.5		80.0		85.0	
BMI,kg/m ²	22.18		25.25		27.76	
Medical illness	hypertension,nephrolithiasis,gout				hypertension,nephrolithiasis,fatty liver,renal cyst,gout	
Disease stage	acute flare	remission	acute flare	remission	acute flare	remission
Dual source CT, tophi	positive		positive		positive	
Duration of gout	20		20		2	
Use of urate-lowering therapy at the time of their entry flare	yes		yes		yes	
Use of anti-inflammatory agents, including colchicine and anti-IL1 therapy, at the time of their flare (besides steroids and NSAIDs)	No		No		No	
Red blood cell count, X10 ¹² /L, (4.30-5.80)	4.03	4.85	4.40	4.27	4.82	4.97
Haemoglobin, g/l, (130-175)	128.00	143.00	144.00	138.00	140.00	147.00
White blood cell count, X10 ⁹ /L, (3.50-9.50)	9.21	7.80	10.90	6.68	7.09	6.91
Platelet count, X10 ⁹ /L, (125-350)	338.00	329.00	179.00	195.00	310.00	221.00
Neutrophil percentage, %, (40-75)	63.90	57.10	66.30	53.90	64.10	62.40
Lymphocyte percentage, %, (20-50)	23.00	31.20	22.20	34.40	28.10	28.90
Monocyte percentage, %, (3-10)	8.70	6.70	9.70	8.70	5.50	6.00
Eosinophils percentage, %, (0.4-8)	3.50	4.50	1.50	2.40	1.90	2.40
Basophils percentage, %, (0-1)	0.90	0.50	0.30	0.60	0.40	0.30
C-reactive protein, mg/L, (<8.2)	6.97	2.43	12.40	2.59	38.82	3.95
Alanine aminotransferase, IU/L, (9-50)	16.70	14.50	39.00	24.50	19.90	6.80
Aspartate aminotransferase, IU/L, (15-40)	18.20	14.10	52.30	18.20	21.20	25.10
Total protein, g/L, (65-85)	76.70	72.50	78.60	71.50	81.30	76.60
Albumin, g/L(40-55)	43.30	41.10	45.80	43.20	48.00	49.50
Fasting Blood Glucose, mmol/L, (3.9-6.1)	4.50	4.61	5.00	5.30	4.70	4.80
Urea, mmol/L, (2.76-8.07)	6.25	5.90	8.11	5.40	4.19	3.54
Estimated Glomerular Filtration Rate, ml/min/L, (>90)	87.94	90.23	145.95	91.41	115.68	124.45
Serum Creatine, umol/L, (57-97)	87.00	84.00	81.20	83.00	82.00	72.00
Uric acid, umol/L, (208-428)	486.00	512.00	335.00	522.00	533.00	646.00
Total Cholesterol, mmol/L, (<5.2)	2.95	3.76	2.68	3.33	4.66	4.80
Triglyceride, mmol/L, (<1.7)	1.93	2.59	1.97	2.92	1.19	1.30
High-Density Lipoprotein, mmol/L, (1.04-1.55)	1.16	1.10	1.20	1.70	0.69	1.01
Low-Density Lipoprotein, mmol/L, (<3.34)	0.93	2.09	0.53	1.20	3.28	3.15

Supplemental Table 8 Baseline characteristics and laboratory findings of good form and good retention in an independent validation cohort

Sample ID	Group	Gender	Age, years	Height, cm	Weight, kg	DM/leg ²	Red blood cell count, 10 ¹² /L	Hemoglobin, g/l	White blood cell count, 10 ⁹ /L	Platelet count, 10 ⁹ /L	Neutrophil percentage, %	Lymphocyte percentage, %	Monocyte percentage, %	Eosinophil percentage, %	Basophil percentage, %	Ureae, mmol/L	Insulin, mU/L	Serum Creatinine, μ mol/L	HbA1c, mmol/L
AG1	Acute flare	male	72	168	65	23.83	3.14	96	12.13	218	86.2	7.1	6.4	0.2	0.1	16.7	15.2	219	574
A2	Acute flare	male	43	175	83	26.37	4.89	109	12.77	200	76.9	12.4	6.4	2.2	0.1	79.5	3.41	79.6	565.1
AG4	Acute flare	male	61	172	73	24.65	4.86	109	5.99	166	59.9	33.6	5.7	2.8	1	40.3	5.8	80	564
AG7	Acute flare	male	51	176	83	27.10	5.55	178	5.52	171	57.1	32.5	7.8	2.2	0.4	24.4	5.1	102	397
A8	Acute flare	male	32	175	75	24.49	2.22	164	4.65	265	69.9	26.9	6.9	3	0.2	34	4.9	74	620
A9	Acute flare	male	34	173	76	25.39	2.62	173	11.15	239	74.1	20.4	5	0.3	0.2	60.7	7.88	101.9	437.4
A10	Acute flare	male	26	175	75	24.49	5.17	163	13.32	200	78.8	15	5.6	0.5	0.1	38.2	4.73	92.9	565.3
A13	Acute flare	male	46	175	80	26.12	5.61	164	6.12	203	68.7	17.5	6.2	0.2	0.4	14.3	5.3	91	543
AG12	Acute flare	male	55	170	65	22.49	5.07	154	6.58	200	72.5	30.2	6.43	0.3	0.4	18.2	4.6	116	421
AG11	Acute flare	male	34	173	80	26.87	5.41	165	16.38	201	80.1	12.5	5.1	2.1	0.2	27.4	4.43	82.7	620.3
AG14	Acute flare	male	49	173	81	27.06	5.04	148	10.26	244	62.9	29.9	6.2	0.9	0.1	49	4.10	85.6	456.6
AG16	Acute flare	male	53	175	80	28.88	5.17	166	6.21	212	62.1	25.9	6.9	1.9	0.2	24.5	4.84	68.7	491
AG21	Acute flare	male	34	182	90	27.17	5.51	157	6.62	208	80.4	29.2	8.2	1.8	0.4	31	4.87	79.5	592.3
AG23	Acute flare	male	58	176	65	26.96	5.93	155	9.84	235	78.8	12.4	7.6	1	0.2	19.4	6.91	125.7	545.1
AG24	Acute flare	male	59	179	75	23.87	5.74	139	9.22	196	63.1	27.6	6.2	0.5	0.4	9.8	4.72	69.6	452.5
AG33	Acute flare	male	43	170	65	22.48	5.17	155	10.35	201	76	19	4	0.8	0.2	89.5	2.42	54.4	477.6
AG35	Acute flare	male	33	180	81	25.00	5.27	168	7.25	219	69.6	22.7	6.2	0.3	0.2	27.7	4.14	82.9	455.6
AG40	Acute flare	male	35	172	83	28.86	5.56	164	10.36	210	65	26.8	7.7	0.4	0.1	33.2	5	89	283
AG41	Acute flare	male	54	164	74.5	27.70	5.18	155	7.54	197	74.3	16.6	6.4	0.5	0.2	47.1	3.84	79.3	177.2
AG42	Acute flare	male	40	179	86	26.84	4.88	151	4.84	338	54.6	37.2	4.7	2.6	0.9	27.1	4.82	74.8	416.4
AG43	Acute flare	male	56	165	65.5	25.16	3.8	100	7.88	236	82.9	13	3.5	0.3	0.3	4	9.6	193	609
AG44	Acute flare	male	33	175	72	23.51	5.24	153	7.88	200	65.4	33.6	5.6	2	0.4	32.3	4.55	77.4	525.9
AG49	Acute flare	male	44	172	75	23.35	5.25	158	9.88	229	69.2	23.1	6.3	1.9	0.5	35.8	4.33	111.9	524.7
AG50	Acute flare	male	38	175	75	24.49	4.75	154	6.77	200	71.5	22.6	4.8	0.6	0.3	24.2	5.54	100.2	474.2
AG2	Acute flare	male	35	178	78	24.82	5.02	158	11.43	200	62.6	27	7.9	1.2	0.3	25.6	4.1	84	687
AG53	Acute flare	male	42	170	75	25.95	4.75	151	5.78	176	59.9	30.7	7.6	1.3	0.5	89.6	5.76	82.3	591.9
AG54	Acute flare	male	62	186	90	26.91	5.3	165	6.88	186	69.9	31.7	5.5	1.7	0.2	26.5	4.89	61.7	568.3
AG55	Acute flare	male	58	182	90	27.17	5	149	7.28	208	75.3	17.8	5.6	1.1	0.2	21.7	5.91	47.5	606.6
AG56	Acute flare	male	50	170	80	31.14	4.5	143	6.13	214	70.5	24.3	3.7	1.3	0.2	32.1	4.33	92	528.5
AG58	Acute flare	male	34	178	85	26.83	4.85	156	6.37	219	67.1	23.9	3.9	1.6	0.4	20.3	5.91	76.4	453.6
AG59	Acute flare	male	40	180	100	30.86	5.22	159	10.05	270	54.9	34.5	6.4	4	0.3	88.2	5.5	79.7	546
P1	Acute flare	male	53	177	68.5	22.18	4.93	128	9.21	338	63.9	23	6.7	3.5	0.9	16.7	6.25	67	636
P2	Acute flare	male	53	170	80	25.25	4.4	144	10.9	179	66.2	22.2	9.7	1.5	0.3	36	6.11	81.2	335
AG3	Acute flare	male	38	172	84	31.77	5.08	155	7.28	233	66.2	37.4	5	1.3	0.1	79	3	83	549
P3-A	Acute flare	male	23	175	65	27.76	4.82	146	7.88	310	64.1	28.1	6.5	1.9	0.4	19.8	4.19	82	533
AG5	Acute flare	male	27	178	88	30.83	4.94	155	8.07	275	69.9	25.3	6.4	1.1	0.3	192.8	4.24	96	798
AG6	Acute flare	male	52	170	70	24.22	4.69	158	7.35	205	47.8	36.4	6.8	0.3	0.7	21.9	5.89	91	596
AG8	Acute flare	male	50	169	70	24.51	4.22	115	6.96	275	67.1	28.3	6.3	6	0.3	5.9	4.26	165	628
AG9	Acute flare	male	31	173	75	25.86	4.69	144	5.26	205	65.7	25.3	6.6	0.7	0.7	6	5.48	87	454
AG10	Acute flare	male	47	170	80	27.68	5.4	127	7.18	288	63	26.4	6.2	2	0.4	42.4	3.88	76	302
AG13	Acute flare	male	64	170	80	27.68	5.74	114	6.3	207	58.5	29	7.6	2.6	0.3	22.8	6.51	111	666
AG15	Acute flare	male	68	170	71	24.87	4.93	149	5.96	200	49	37	10.5	2.8	0.7	10.8	6.10	82	546
AG19	Acute flare	male	64	170	66	22.84	3.36	92	7.23	310	67.1	24.6	5.8	2.4	0.1	37	13.9	173	516
AG17	Acute flare	male	35	165	105	38.57	5.31	154	6.71	415	67.8	30.3	6.4	2.6	0.9	78.7	4.4	74	723
AG20	Acute flare	male	67	176	71	22.82	4.33	134	4.27	188	66.7	33.2	8	1.6	0.5	9.2	4.7	138	391
AG18	Acute flare	male	55	168	78	27.44	4.78	146	6.65	245	47.6	40.2	6.1	3.3	0.3	20.1	2.9	63	316
P3-B	Remission	male	23	175	65	27.76	4.97	147	6.91	221	62.4	28.9	6	2.4	0.3	6.8	2.54	72	646
G2	Remission	male	43	175	83	28.37	5.15	157	7.91	213	66.7	26.1	6.8	0.1	0.5	67	5.6	73	487
G7	Remission	male	77	165	82	30.12	4.38	148	5.98	247	55.9	30.8	10.4	2.2	0.7	64.1	5.9	77	507
G8	Remission	male	32	175	76	24.49	6.91	169	8.91	233	61.5	30.2	5.6	2.4	0.3	25.1	4.2	80	454
G9	Remission	male	34	173	76	25.39	5.4	164	6.38	223	63.9	28.8	6.5	0.5	0.3	40.5	4.7	86	498
G10	Remission	male	46	175	80	26.12	5.45	151	7.85	237	65	24	5	5.5	0.5	24.9	4.4	79	369
G13	Remission	male	55	170	65	22.49	5.01	164	5.87	185	62.7	26.1	5.7	1.1	0.4	24.2	6.7	129	622
RG42	Remission	male	40	179	84	24.84	4.9	149	6.2	233	48.9	42.8	6.3	2.8	0.6	60.7	4.8	77	493
RG43	Remission	male	56	165	65.5	25.16	4.19	112	7.47	165	75.7	19.7	5.3	0.4	0.1	5.7	14	220	596
RG2	Remission	male	35	178	78	24.82	4.68	148	8.88	283	67.6	32	6	2.1	0.3	31	3.3	62	645
G22	Remission	male	45	180	76	23.46	5.21	159	5.87	273	69.1	26.6	4.4	0.7	0	21.9	4.87	82.6	473.3
G23	Remission	male	53	181	95	29.00	5.26	159	5.87	229	59.8	32.2	6.6	0.9	0.5	24.6	6.7	87	732
RG28	Remission	male	33	180	86	26.32	5.4	157	5.26	255	47	36.9	11.8	3	1.3	16.5	5.4	79	556
RG29	Remission	male	52	170	70	24.22	4.75	153	6.29	226	62	27.2	7.1	2.1	0.6	36	6.7	93	591
RG30	Remission	male	27	168	88	31.18	4.97	154	6.96	247	49.1	41.8	6.5	2.1	0.5	68.8	3.3	99	507
RG31	Remission	male	76	172	75	25.35	3.25	111	5.66	157	67.9	22.6	7.4	1.4	0.5	12.5	10.4	122	486
RG9	Remission	male	71	165	80	29.36	4.53	105	10.57	289	48.2	40.2	7	2.9	0.7	11.5	6.9	121	372
RG11	Remission	male	45	174	70	23.12	5.13	146	5.58	209	65.6	33.4	6.7	1.7	0.6	21.5	4.6	92	403
RG14	Remission	male	55	182	84	25.86	5.04	164	7.71	212	75.9	17.2	5.8	1	0.1	22.5	4.1	104.6	923
RG15	Remission	male	68	174	85	28.88	4.16	128	6.25	234	64.9	25.1	7.5	1.9	0.6	22.6	7.8	141	446
RG29	Remission	male	54	172	80	27.84	5.85	165	6.91	188	64.5	27.7	6.3	2.1	0.4	40.3	5.1	72	497
RG1	Remission	male	56	177	78.8	25.15	4.63	149	7.2	175	68.4	27.1	10.4	3.3	0.8	19.3	6	74	535
RG2	Remission	male	56	170	73.4	23.17	4.15	126	6.27	180	62.9	32.9	10.5	2.9	0.9	37	6.6	81	411
RG3	Remission	male	59	168	75	24.49	6.26	126	4.42	217	74.4	16.6	7.7	1	0.3	21	9.5	120	458
RG4	Remission	male	56	173	65	21.72	5.1	155	5.91	189	61.7	30.5	5.5	3.5	0.3	22.7	4	95	664
RG5	Remission	male	65	169	74	25.91	4.93	168	4.65	135	66.1	26.5	6.2	2.5	0.7	14.1	5.3	112	605
RG6	Remission																		

Supplemental Table 8 Antibodies for cell staining required by flow cytometry

Celltype	Marker
Leukocyte	CD45 ⁺
Myeloid cell	CD45 ⁺ CD11b ⁺
Classical monocyte	CD45 ⁺ CD11b ⁺ CD14 ⁺ CD16 ⁻
Non-classical monocyte	CD45 ⁺ CD11b ⁺ CD16 ⁺ CD14 ⁻
HLA-DQA1 ⁺ classical monocyte	CD45 ⁺ CD11b ⁺ CD14 ⁺ CD16 ⁻ HLA-DQA1 ⁺
HLA-DQA1 ⁺ non-classical monocyte	CD45 ⁺ CD11b ⁺ CD16 ⁺ CD14 ⁻ HLA-DQA1 ⁺
T cells	CD45 ⁺ CD3 ⁺
CD4 ⁺ T cells	CD45 ⁺ CD3 ⁺ CD4 ⁺
Th1 cells	CD45 ⁺ CD3 ⁺ CD4 ⁺ CXCR5 ⁻ CXCR3 ⁺ CCR4 ⁻
Th2 cells	CD45 ⁺ CD3 ⁺ CD4 ⁺ CXCR5 ⁻ CXCR3 ⁻ CCR4 ⁺
Th17 cells	CD45 ⁺ CD3 ⁺ CD4 ⁺ CXCR5 ⁻ CXCR3 ⁻ CCR4 ⁺ CCR6 ⁺
Treg cells	CD45 ⁺ CD3 ⁺ CD4 ⁺ CD25 ⁺ CD127 ⁻

Supplemental Table 9 the source for commercial antibodies

Antibody	source	catalog number
CD45-FITC	BD Pharmingen	555482
Fixable viability stain 780	BD Pharmingen	565388
CD11B-PerCP-Cy5.5	BioLegend	393106
CD14-APC	BD Pharmingen	555399
CD16-PE-Cy7	BD Pharmingen	560716
HLA-DQA1-PE	Novus	NBP3-08747PE
CD3-PerCP-Cy5.5	BD Pharmingen	560835
CD4-APC-H7	BD Pharmingen	560158
CXCR5-AF647	BD Pharmingen	558113
CXCR3-AF488	BD Pharmingen	558047
CCR4-BV421	BD Pharmingen	562579
CCR6-BV510	BD Pharmingen	563241
CD25-PE	BD Pharmingen	555432
CD127-BV421	BD Pharmingen	562436